Introduction
Genetic defects in the trans-Golgi copper-transporter P-ATPase, ATP7A, cause three distinct X-linked recessive disorders: occipital horn syndrome (OMIM 304150), spinal muscular atrophy, distal, X-linked 3 (SMAX3, OMIM 300489), and Menkes disease (OMIM 309400) (Kaler, 2011) . More than 350 different mutations affecting the ATP7A gene have been described (Moller et al., 2009; Tumer, 2013) . These disease-associated mutations are quite heterogeneous in their genomic location and the type of DNA defect and, unlike other genetic disorders, there are no recurrent genetic defects that account for a significant number of cases (Tumer, 2013) . Milder mutations in ATP7A result in occipital horn syndrome in which connective tissue and bone abnormalities predominate and patients lack the severe neurological phenotypes of Menkes disease (Das et al., 1995; Kaler et al., 1994 ). Yet another ATP7A-related disease is SMAX3, in which missense mutations not severe enough to perturbate systemic copper status cause a nondemyelinating spinomuscular atrophy (Kennerson et al., 2010; Takata et al., 2004) . At the far end of the spectrum is Menkes disease in which the most severe loss-of-function mutations result in a multisystemic metabolic disorder of copper deficiency. Here we focus in Menkes disease, first described in 1962 in a single family that in two generations accumulated five male infants affected by intellectual disability, failure to thrive, prominent neurological manifestations, neurodegeneration, epilepsy, and 'peculiar white hair ' (Menkes et al., 1962) . Menkes disease is a rare affliction with an incidence of 1/140,000 to 1/300,000 (Gu et al., 2005; Tonnesen et al., 1991) . Although this disease has been studied for more than 50 years and its metabolic foundations are known (Kaler, 2011; Menkes, 1988) , we contend that the pathogenic mechanisms underlying neurodegeneration and neurodevelopmental defects remain poorly understood. In this review, we explore neuropathogenic hypotheses and argue that some of the classic ideas invoked to explain Menkes disease phenotypes, although logical, remain speculative and inadequate. We propose an updated modified hypothesis in light of newer findings to account for the neurological manifestations of ATP7A loss-of-function mutations.
Our interest in Menkes disease pathogenesis extends beyond this genetic disorder. Because the neurological symptoms associated with Menkes disease are common to other neuropsychiatric disorders of childhood and adulthood (Kaler, 2011; Menkes, 1988) , it is increasingly recognized that Menkes disease studies may shed light into the mechanisms of other prevalent disorders. Menkes pathogenesis mechanisms can thus be a tool to understand: a) neuronal mechanisms where copper participates either as a micronutrient or a toxicant; b) pathways of neuronal cell death triggered by altered metabolic homeostasis; c) mechanisms that cells use to respond to neurotoxic anticancer agents such as platinum compounds, which bind to ATP7A (Gregg et al., 1992; Neurobiology of Disease 81 (2015) 154-161 
